The comparison of pregnancy-related attack between patients with NMOSD with AQP4-ab and MOG-ab
| AQP4 cohort | MOG cohort | P value | |
| Number of patients | 42 | 16 | — |
| Age at disease onset, year, median (range) | 27.9 (20.6–42.8) | 28.3 (22.9–38.0) | 0.727 |
| Age at delivery/abortion, year, median (range) | 27.9 (20.1–42.7) | 28.3 (23.0–37.2) | 0.793 |
| Number of pregnancy-related attacks, median (range) | 1 (1–4) | 1 (1–3) | 0.944 |
| Number of pregnancy-related attacks, n (%) | |||
| DP1 | 4 (6.3) | 2 (8.3) | 0.666 |
| DP2 | 2 (3.2) | 0 (0) | 1.000 |
| DP3 | 2 (3.2) | 0 (0) | 1.000 |
| PP1 | 25 (39.7) | 9 (37.5) | 0.852 |
| PP2 | 15 (23.8) | 4 (16.7) | 0.471 |
| PP3+4 | 15 (23.8) | 9 (37.5) | 0.202 |
| Type of pregnancy-related attacks, n (%) | |||
| Optic neuritis | 24 (38.1) | 19 (79.2) | <0.001** |
| Acute myelitis | 33 (52.4) | 6 (25.0) | 0.022* |
| Area postrema syndrome | 16 (25.4) | 1 (4.2) | 0.054 |
| Acute brainstem syndrome | 3 (4.8) | 0 (0) | 0.558 |
| Patient with concomitant auto-antibodies, n (%) | 23 (54.8) | 2 (12.5) | 0.004** |
| ANA | 20 (47.6) | 1 (6.3) | 0.003** |
| ENA-ab | 13 (31.0) | 1 (6.3) | 0.105 |
| dsDNA-ab | 2 (4.8) | 0 (0) | 1.000 |
| ANCA | 0 (0) | 0 (0) | — |
| ACA | 1 (2.4) | 0 (0) | 1.000 |
| TPO-ab and TG-ab | 12 (28.6) | 2 (12.5) | 0.350 |
| EDSS score in exacerbation phase, median (range) | 4 (3–9) | 4 (3–7.5) | 0.428 |
| EDSS score in remission phase, median (range) | 2 (0–9) | 1 (0–7.5) | 0.003** |
*P< 0.05, **p< 0.01.
ACA, anticardiolipin antibody; ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody; AQP4-ab, aquaporin-4 antibody; DP, during pregnancy; dsDNA-ab, double-stranded DNA antibody; EDSS, Expanded Disability Status Scale; ENA-ab, extractable nuclear antigen antibody; MOG-ab, myelin oligodendrocyte glycoprotein antibody; NMOSD, neuromyelitis optica spectrum disorder; PP, postpartum period; TG-ab, thyroglobulin antibody; TPO-ab, thyroid peroxidase antibody.